Prevention of Peritoneal Sclerosis: A New Proposal to Substitute Glucose with Carnitine Dialysis Solution (Biocompatibility Testing in Vitro and in Rabbits)
Restricted accessResearch articleFirst published online February, 2005
Prevention of Peritoneal Sclerosis: A New Proposal to Substitute Glucose with Carnitine Dialysis Solution (Biocompatibility Testing in Vitro and in Rabbits)
Commercial glucose peritoneal dialysis solutions expose the peritoneum to hyperosmolar glucose containing variable amounts of non-enzymic breakdown products of glucose. These solutions are toxic for the peritoneum. The aim of the present study is to compare in vitro and in vivo characteristics of a new dialysis solution containing carnitine, a naturally occurring compound, as substitute of glucose.
Material and Methods
We compared in vitro and in the rabbit a new peritoneal dialysis solution containing carnitine, with two standard bicarbonate glucose peritoneal dialysis solutions and a solution containing icodextrin.
Results
In vitro and in vivo the solution containing carnitine seems to be more biocompatible than standard glucose solutions and those containing icodextrin.
Conclusions
In our study the peritoneal dialysis solution containing carnitine seems to prevent the mesothelial changes observed with solutions containing glucose. Since carnitine has been extensively studied and seems to be well tolerated by hemodialysis patients, even at high doses for long periods, clinical trials in humans may be planned in the near future.
Di PaoloN., GarosiG., TraversariL., Di PaoloM.Mesothelial biocompatibility of peritoneal dialysis solutions. Perit Dial Int1993; 1(suppl 2): S109–12.
2.
Di PaoloN., GarosiG., PetriniG., TraversariL., RossiP.Peritoneal dialysis solutions testing in animals. Perit Dial Int1995; 15(suppl 7): S61–70.
3.
Di PaoloN., GarosiG., PetriniG., MonaciG.Morphological and morphometric changes in mesothelial cells during peritoneal dialysis in the rabbit. Nephron1996; 74: 594–9.
4.
Di PaoloN., GarosiG., BiagioliM.Effects of dialysis fluids on cultured mesothelial cells. Perit Dial Int1994; (suppl 3): S12–5.
5.
Di PaoloN., BuoncristianiU., CapotondoL.Phosphatidylcholine and peritoneal transport during peritoneal dialysis. Nephron1986; 44: 365–70.
6.
Di PaoloN., SacchiG., VanniL.Autologous peritoneal mesothelial cell implant in rabbits and peritoneal dialysis patients. Nephron1991; 57: 323–31.
7.
Di PaoloN., SacchiG.Atlas of peritoneal histology. Perit Dial Int2000; 20(suppl 3): S1–100.
8.
HolmesC.J.Biocompatibiliuty of peritoneal dialysis solutions. Perit Dial Int1991; 13: 88–94.
9.
JorresA., TopleyN., GahlG.M.Biocompatibility of peritonenal dialysis fluids. Int J Artif Organs1992; 15: 79–83.
10.
GarosiG., GaggiottiE., MonaciG., BrardiS., Di PaoloN.Biocompatibility of peritoneal dialysis solution with amino acids: Histological evaluation in the rabbit. Perit Dial Int1998; 18: 610–9.
11.
JohnsonD.W., AgarJ., CollinsJ., DisneyA., HarrisD.C., IbelsL., IrishA., SaltissiD., SuranyiM.Recommendations for the use of icodextrin in peritoneal dialysis patients. Nephrology2003; 8: 1–7.
12.
ArduiniA.Use of L-carnitine ands its alkanoyl derivatives as osmotic agents in solutions for medical use. Patent n. WO 01/26649 (2001).
13.
Di PaoloN., SacchiG.Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangiopathy. Perit Dial Int1989; 9: 41–5.
14.
Di PaoloN.The peritoneal mesothelium. An excretory organ. Perit Dial Int1989; 9: 151–4.
15.
SchambyeH.T., FlesnerP., PedersenR.B., Hardt-MadsenM., ChemnitzJ., ChristensenH.K., DetmerA., PedersenF.B.Bicarbonate -versus lactate-based CAPD fluids: A biocompatibility study in rabbits. Perit Dial Int1992; 12: 281–6.
16.
CookerL.A., HolmesC.J., HoffC.M.Biocompatibility of icodextrin. Kidney Int2002; 81(suppl): S34–45.
ZammitV.Carnitine acyltransferases: Functional significance of subcellular distribution and membrane topology. Progr Lipid Res1999; 38: 199–224.
20.
UzielG., GaravagliaB., Di DonatoS.Carnitine stimulation of pyruvate dehydrogenase complex (PDHC) in isolated human skeletal muscle mitochondria. Muscle Nerve1998; 11: 720–4.
21.
ArduiniA., MancinelliG., RadattiG.L.Role of carnitine palmitoyltransferase in membrane phospholipid fatty acid turnover in human erythrocyte. J Biol Chem1992; 267: 12673–81.
22.
BieberL.L.Carnitine. Ann Rev Biochem1998; 57: 261–83.
23.
PonsR., De VivoD.C.Primary and secondary carnitine deficiency syndromes. J Child Neurol1995; 10(suppl): S8–24.
24.
HurotJ.M., CucheratM., HaughM., FouqueD.Effects of L-carnitine supplementation in maintenance hemodialysis patients: A systematic review. J Am Soc Nephrol2002; 13: 708–14.
25.
Wieczorowska-TobisK., BrelinskaR., WitowskiJ.Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. Perit Dial Int2004; 24: 48–57.
26.
WitowskiJ., KorybalskaK., KsiazekK., Wisniewska-ElnurJ.Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant2004; 19: 917–24.
27.
MortierS., De VrieseA.S., LameireN.Recent concepts in the molecular biology of the peritoneal membrane - implications for more biocompatible dialysis solutions. Blood Purif2003; 21: 14–23.
28.
WitowskiJ., BenderT.O., Wisniewska-ElnurJ., KsiazekK.Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. Perit Dial Int2003; 23: 381–90.
29.
AmoreA., CappelliG., CirinaP., ContiG.Glucose degradation products increase apoptosis of human mesothelial cells. Nephrol Dial Transplant2003; 18: 677–88.
30.
WieslanderA., LindenT., KjellstrandP.Glucose degradation products in peritoneal dialysis fluids: How they can be avoided. Perit Dial Int2001; 21(suppl 3): S119–24.
